The US FDA reorganises its review functions
16 March 2010
Nancy Faigen
The
US FDA has realigned various review functions of its six Offices of Drug Evaluation (ODE) within the Center for Drug Evaluation and Research's Office of New Drugs in order to enhance the logical groupings of applications.
The realignment, which took place on 15 March, is designed to achieve...
Please Login to read the full article.
16 March 2010
Nancy Faigen
The realignment, which took place on 15 March, is designed to achieve...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: PhRMA hopes Part D savings will be muscle against 'Super Congress' cuts
- US Capitol Capsule: US drug shortages worsen, putting patients increasingly at risk
- US Capitol Capsule: IOM analysis finds little evidence of vaccine harm, debunks autism link
- A year in pharma and biotech R&D: Healthy numbers belie lack of novelty
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
